Retatrutide
WellnessAlso known as: LY3437943, Reta
Emerging ResearchWhat is Retatrutide?
A triple hormone receptor agonist (GLP-1/GIP/glucagon) developed by Eli Lilly, representing the next generation of obesity treatments beyond semaglutide and tirzepatide. Phase III trials (TRIUMPH-1) have now shown weight loss of up to 28.3% of body weight at 80 weeks, up from the 24.2% seen in earlier Phase II data.
How it works
Simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying), GIP (enhances insulin secretion, may improve fat metabolism), and glucagon (increases energy expenditure, promotes fat oxidation in the liver). The triple mechanism is thought to produce greater weight loss than dual or single agonists.
What marketers claim
- ▸the most powerful weight loss drug ever made
- ▸will replace semaglutide entirely
- ▸no side effects compared to GLP-1 drugs
- ▸cures obesity permanently
What evidence supports
- ✓Phase III TRIUMPH-1 trial (obesity, ~2,339 adults) showed 28.3% average weight loss at 80 weeks at the top dose, with close to half of participants losing 30% or more — surpassing the earlier Phase II ceiling
- ✓TRIUMPH-4 (obesity plus knee osteoarthritis) showed a similar 28.7% loss at 68 weeks
- ✓TRANSCEND-T2D-1 showed 16.8% weight loss in people with type 2 diabetes at 40 weeks
- ✓improvements in metabolic markers including HbA1c, triglycerides, and liver fat
- ✓glucagon component may provide additional liver fat reduction and energy expenditure
Research evidence
Key studies on Retatrutide, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Retatrutide once weekly for treatment of obesity (TRIUMPH-2 Phase II)
Finding: At the highest dose (12mg), participants lost an average of 24.2% body weight at 48 weeks. All dose levels produced significantly greater weight loss than placebo.
Limitation: Phase II trial — smaller sample size and shorter duration than the Phase III trials that have since reported results. Superseded by TRIUMPH-1 below for weight-loss magnitude, though it remains the earliest evidence in this program.
TRIUMPH-1: Retatrutide Phase III trial for obesity
Finding: At 80 weeks, the top dose produced an average 28.3% body weight loss, with close to half of participants losing 30% or more.
Limitation: Longest follow-up so far is 80 weeks — durability beyond that and long-term cardiovascular safety are not yet established. Pre-approval trial data.
TRANSCEND-T2D-1: Retatrutide in type 2 diabetes
Finding: In adults with type 2 diabetes, retatrutide produced 16.8% average weight loss at 40 weeks alongside glycemic improvements.
Limitation: Weight loss is lower than in the non-diabetic obesity trials, consistent with the general pattern seen across GLP-1-class drugs in diabetic populations. Pre-approval trial data.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Week 1-4
Dose escalation phase. Appetite reduction and nausea are common. Weight loss begins, typically 2-4% of body weight in the first month.
Month 2-3
GI side effects often improve as the body adjusts. Weight loss accelerates. Metabolic markers begin improving.
Month 6-9
In earlier phase II trials, participants reached approximately 17-22% weight loss at these timepoints depending on dose; Phase III data shows a similar trajectory continuing further.
Month 12+
Phase III TRIUMPH-1 data shows weight loss continuing well past the 48-week Phase II endpoint, reaching 28.3% average loss at 80 weeks (up to ~18.5 months) at the top dose. Ongoing use is likely needed to maintain weight loss.
Safety notes & concerns
Full safety guide →- ⚠still in clinical development — not yet FDA approved
- ⚠Phase III data is now published for several indications, but the drug has not completed the full approval process; a BLA submission is reportedly targeted for around Q1 2027
- ⚠gastrointestinal side effects (nausea, diarrhea, vomiting) are common, especially during dose escalation
- ⚠gallbladder and pancreatitis events have been tracked across trials, with gallbladder-related risk appearing to rise with the degree of weight loss achieved — worth extra attention given retatrutide produces more weight loss than its GLP-1-class peers
- ⚠long-term cardiovascular outcome data is not yet available
- ⚠weight regain after discontinuation is expected based on GLP-1 class data
- ⚠black market versions are already circulating with unknown contents
Pairs well with
Use caution with
Frequently asked questions
How is Retatrutide different from semaglutide and tirzepatide?
Semaglutide (Ozempic/Wegovy) targets only GLP-1. Tirzepatide (Mounjaro/Zepbound) targets GLP-1 and GIP. Retatrutide adds a third target — glucagon receptors — which increases energy expenditure and fat oxidation. Each generation has shown incrementally greater weight loss in clinical trials, and Phase III data now confirms this pattern continues for retatrutide.
When will Retatrutide be available?
Eli Lilly has now published Phase III results (TRIUMPH-1, TRIUMPH-4, TRANSCEND-T2D-1) and is reportedly targeting a regulatory submission (BLA) to the FDA around Q1 2027. That would put approval and market availability sometime after that, following FDA review. It is not currently available through any legitimate clinical channel outside of clinical trials.
Is it safe to buy Retatrutide online now?
No. Any product sold as retatrutide outside of clinical trials is unregulated and may contain incorrect doses, contaminants, or entirely different substances. There is no way to verify the contents of black market peptides. Wait for the approved pharmaceutical product.
Related wellness peptides
skin hydration support, joint comfort, general wellness
clinically obese patients under physician supervision, type 2 diabetes management
those following longevity research who pursue protocols with medical supervision
understanding as a cautionary example of peptide marketing vs evidence
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with Retatrutide
Last updated: 2026-09-25
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.